Purple Biotech (PPBT) Ownership - Who owns Purple Biotech?

Key Takeaways

• Purple Biotech Ltd (PPBT) is a clinical-stage biotechnology company headquartered in Rehovot, Israel, focused on oncology therapies that target tumor immune evasion and drug resistance.
• The company was formerly known as Kitov Pharma Ltd and adopted the Purple Biotech name in December 2020, with corporate roots dating back to 1968.
• Its pipeline centers on the CAPTN-3 tri-specific antibody platform, alongside earlier clinical candidates CM24 and NT219.
• As a clinical-stage developer, Purple Biotech has no approved products and generates no meaningful revenue, meaning its financial profile is defined by research spending and net losses.
• Purple Biotech maintains a collaboration agreement with Bristol Myers Squibb (BMY) to evaluate CM24 in combination with the PD-1 inhibitor nivolumab.

Introduction

Purple Biotech Ltd is a clinical-stage biotechnology company that develops next-generation oncology therapies intended to help the immune system overcome tumor immune evasion and drug resistance. Investors follow PPBT primarily because of its early-stage antibody platform and pipeline rather than for current sales or earnings. The company does not yet market any approved products, so its value proposition is tied closely to the progress of its drug candidates through preclinical and clinical development.

Main Profile

Purple Biotech Ltd is headquartered in Rehovot, Israel, and its shares trade on the Nasdaq and Tel Aviv Stock Exchange under the ticker PPBT. The company traces its corporate history to 1968 and was previously known as Kitov Pharma Ltd before rebranding as Purple Biotech in December 2020. This renaming reflected a strategic shift toward a focused oncology pipeline.

At the center of Purple Biotech's business model is its CAPTN-3 platform, a modular technology for creating tri-specific antibodies — engineered proteins designed to bind multiple targets at once and activate an anti-tumor immune response. The lead candidate from this platform is IM1240, a tri-specific antibody targeting the tumor-associated antigen 5T4, with a second candidate, IM1305, targeting TROP2. These programs are largely preclinical, though the company has reported preclinical data and manufacturing milestones intended to support advancement toward clinical testing.

Purple Biotech's broader pipeline also includes two earlier clinical candidates. CM24 is a humanized monoclonal antibody that blocks CEACAM1, a protein involved in immune suppression, and is being studied in a Phase 2 trial for pancreatic ductal adenocarcinoma in combination with an anti-PD-1 checkpoint inhibitor. NT219 is a small molecule designed to inhibit IRS1/2 and STAT3, and has been evaluated in Phase 2 studies for recurrent or metastatic head and neck cancer and colorectal adenocarcinoma. The company also maintains a collaboration with BMY to evaluate CM24 together with nivolumab and chemotherapy.

Because it has no commercialized products, Purple Biotech's primary revenue source is effectively nonexistent; it relies on equity financing to fund research and development. Its business model therefore depends on advancing its candidates toward regulatory milestones, partnership agreements, or licensing deals rather than on product sales. The company's competitive positioning rests on its differentiated tri-specific antibody technology, but it operates in a highly competitive oncology field alongside larger, better-capitalized biotechnology and pharmaceutical companies.

Why Investors Follow PPBT

Investor attention on PPBT centers on its oncology pipeline and platform technology rather than on traditional fundamentals. The CAPTN-3 tri-specific antibody platform represents a potential point of differentiation, offering a modular design that could be applied across multiple tumor targets. The company's collaboration with Bristol Myers Squibb also lends external validation to its clinical approach and provides a signal of interest from a major pharmaceutical partner.

For investors focused on long-term growth drivers, Purple Biotech's relevance stems from the large and growing market for cancer immunotherapies and the possibility that its platform could yield first-in-class therapies. Progress in preclinical studies, patent allowances, and manufacturing scalability have historically influenced how the market perceives the company's technology. However, because the pipeline is still early stage, the company's financial profile is defined by research expenditures and recurring net losses rather than revenue growth or profitability.

Risks and Important Considerations

Investing in PPBT carries substantial risks typical of clinical-stage biotechnology companies. The company has no approved products, generates little or no revenue, and must fund ongoing research through equity raises, which can dilute existing shareholders. Drug development is inherently uncertain: candidates may fail in clinical trials, encounter safety issues, or face regulatory delays.

Purple Biotech also faces intense competition from larger pharmaceutical and biotechnology firms with greater financial and scientific resources. Its small workforce and reliance on a limited number of early-stage programs create concentration risk — the company's outlook is heavily tied to the success of a few candidates and its CAPTN-3 platform. Regulatory requirements, macroeconomic conditions affecting access to capital, and potential Nasdaq listing compliance considerations are additional factors investors should evaluate before considering the stock.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. The tool lets users efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. For investors researching names like PPBT or exploring oncology-related themes, the AI Screener offers a structured way to narrow the universe and refine a watchlist.

Conclusion

Purple Biotech Ltd is a small, clinical-stage oncology company whose identity is built around its CAPTN-3 tri-specific antibody platform and a pipeline that includes CM24 and NT219. What makes it distinctive is its focus on multi-target antibody engineering aimed at difficult-to-treat, treatment-resistant cancers. For investors, the company represents a high-risk, early-stage exposure to the immunotherapy space — its long-term relevance will depend on whether its candidates can advance successfully through clinical development and demonstrate meaningful anti-tumor activity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations